Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chromadex Corp CDXC

Technology Scientific & Technical Instruments
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished... see more

Recent & Breaking News (NDAQ:CDXC)

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured(TM) Transparency Program

Business Wire March 26, 2024

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Business Wire March 6, 2024

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

Business Wire February 21, 2024

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

Business Wire January 26, 2024

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

Business Wire December 20, 2023

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

PR Newswire December 12, 2023

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Business Wire November 30, 2023

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Business Wire November 15, 2023

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

Business Wire November 9, 2023

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

Business Wire November 8, 2023

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

Business Wire November 1, 2023

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Business Wire October 31, 2023

ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With 'Healthy Aging' Line

Business Wire October 26, 2023

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

Business Wire October 2, 2023

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

Business Wire August 24, 2023

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

Business Wire August 9, 2023

ChromaDex Launches Tru Niagen® with iHerb, the World's Number One Online Destination for Health and Wellness

Business Wire August 8, 2023

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series

Business Wire August 7, 2023

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

Business Wire August 2, 2023

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Business Wire July 18, 2023